Chemomab Therapeutics (CMMB) Assets Average (2019 - 2026)

Chemomab Therapeutics (CMMB) has reported Assets Average for 8 consecutive years, with $11.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Assets Average fell 7.94% year-over-year to $11.0 million; the trailing twelve-month figure through Jun 2026 stood at $11.0 million (down 7.94% YoY), and the FY2025 full-year result was $15.4 million, down 21.32% from the prior year.
• Assets Average fell to $11.0 million in Q2 2026 per CMMB's latest filing, from $12.8 million in the prior quarter.
• Across five years, Assets Average topped out at $62.7 million in Q1 2022 and bottomed at $11.0 million in Q2 2026.
• Historically, Assets Average has averaged $27.2 million across 5 years, with a median of $19.5 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Assets Average soared 72.6% in 2022, then tumbled 51.15% in 2023.
• Over 5 years, Assets Average stood at $46.6 million in 2022, then plunged by 51.15% to $22.8 million in 2023, then decreased by 16.92% to $18.9 million in 2024, then tumbled by 30.85% to $13.1 million in 2025, then fell by 15.79% to $11.0 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $11.0 million, $12.8 million, and $13.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.